Cosmos Health Secures 5-Year, 2.86M-Unit Manufacturing Deal for Dermatological Products
COSM sits 27% above its 52-week low of $0.193.
Summary
Cosmos Health, through its subsidiary Cana Laboratories, has signed a five-year contract manufacturing agreement with Pharmex S.A. for 2.86 million units of three dermatological products. This agreement, averaging 572,000 units annually, aims to increase utilization of Cana's EU manufacturing capacity and strengthen recurring, higher-margin revenue streams. This positive development provides some revenue stability for the company, which recently reported a going concern warning, widened losses, and increased cash burn in its Q1 2026 10-Q filing. While the financial value of the contract is not disclosed, it represents a concrete step towards improving the company's operational and financial health.
At the time of this announcement, COSM was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.2M. The 52-week trading range was $0.19 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.